🇺🇸 FDA
Patent

US 10676533

Methods of treatment of CD123 overexpressing disorders

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10676533 (Methods of treatment of CD123 overexpressing disorders) held by Aptevo Research and Development LLC expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aptevo Research and Development LLC
Grant date
Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P35/00